Spots Global Cancer Trial Database for apixaban 2.5 mg oral tablet [eliquis]
Every month we try and update this database with for apixaban 2.5 mg oral tablet [eliquis] cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients | NCT04243122 | Myeloproliferat... Essential Throm... JAK2 Mutation Polycythemia Ve... Primary Myelofi... Venous Thromboe... | Apixaban 2.5 MG... Aspirin 81 mg | 18 Years - | Ottawa Hospital Research Institute | |
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients | NCT04243122 | Myeloproliferat... Essential Throm... JAK2 Mutation Polycythemia Ve... Primary Myelofi... Venous Thromboe... | Apixaban 2.5 MG... Aspirin 81 mg | 18 Years - | Ottawa Hospital Research Institute | |
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients | NCT04243122 | Myeloproliferat... Essential Throm... JAK2 Mutation Polycythemia Ve... Primary Myelofi... Venous Thromboe... | Apixaban 2.5 MG... Aspirin 81 mg | 18 Years - | Ottawa Hospital Research Institute |